E!12830 - MucoVAC - Timeline Bioresearch
| Reference number | |
| Coordinator | Timeline Bioresearch AB |
| Funding from Vinnova | SEK 3 892 815 |
| Project duration | June 2019 - August 2022 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
The project, aimed to develop a more effective transmucosal vaccination strategy based on a new innovative route of administration. The delivery format is a sublingual oral film with nanofiber technology that is expected to be better when there is a need to obtain a fast onset of drug effect or vaccination. The objective of the project was to show that the technology could be used for vaccination against influenza in a pig model system.
Expected long term effects
Studies in pigs showed that immunizations with H1N1 influenza vaccine on sublingual oral films resulted in elevated levels of antigen specific T-cells and B-cells in lung tissue. This would be particularly important in terms of conferring protection against influenza infection in order to reduce viral loads and the subsequent risk of transmission to susceptible hosts.
Approach and implementation
The project was carried out as planned with vaccination studies on pigs showing successful results. A final part of the project concerning toxicity studies in rodents has also been carried out. No toxicity of the oral films could be detected.